lactate dehydrogenase B pseudogene 3Genealiases: []
Q-omics provides the consensus-scored LDHBP3 profile across patient tissues and cancer cell-line models. LDHBP3 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LDHBP3 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, LDHBP3 RNA expression shows 4,809 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight UCEC, THCA, and KIRC as cancer lineages where LDHBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDHBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDHBP3 survival associations across molecular data types. LDHBP3 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDHBP3 RNA expression–survival associations across cancer types. High LDHBP3 expression shows unfavorable associations in UCEC, THYM, READ, BLCA and LAML, but favorable associations in LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LDHBP3 RNA expression.
This table summarizes LDHBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LDHBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDHBP3 shows lower tumor expression in THCA. The THCA box plot shows higher LDHBP3 RNA expression in normal versus tumor tissue (log2 FC = −0.012, t-test p = .030).
This table shows molecular features associated with LDHBP3 in patient tissues and cancer cell lines. In patient samples, LDHBP3 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
